从DIG试验中吸取的教训

Debra Egan M.Sc., M.P.H. , Nancy Geller Ph.D. , Salim Yusuf M.B.B.S., F.R.C.P. , Rekha Garg M.D., M.S. , Joseph F. Collins Sc.D. , James Mathew M.D. , Edward Philbin M.D. , on behalf of the DIG Investigators
{"title":"从DIG试验中吸取的教训","authors":"Debra Egan M.Sc., M.P.H. ,&nbsp;Nancy Geller Ph.D. ,&nbsp;Salim Yusuf M.B.B.S., F.R.C.P. ,&nbsp;Rekha Garg M.D., M.S. ,&nbsp;Joseph F. Collins Sc.D. ,&nbsp;James Mathew M.D. ,&nbsp;Edward Philbin M.D. ,&nbsp;on behalf of the DIG Investigators","doi":"10.1016/S0197-2456(03)00099-0","DOIUrl":null,"url":null,"abstract":"<div><p>The Digitalis Investigation Group (DIG) trial was the first large simple trial conducted by the National Heart, Lung, and Blood Institute in conjunction with the Department of Veterans Affairs. A large simple trial is a major undertaking. Simplification at the sites requires careful planning and discipline. Lessons learned from the DIG trial were: (1) keep a large simple trial very simple and keep all study procedures very simple; (2) ancillary studies are important and can complement a large simple trial but require careful advanced planning; (3) anticipate special needs when shipping study drugs internationally; (4) regional coordinating centers can be very useful; (5) recruit as many capable sites as possible; (6) provide research-inexperienced sites/investigators with extra help to obtain federalwide assurance statements from the Office for Human Research Protections and institutional review board approvals; (7) adequately reimburse sites for the work completed; (8) maintain investigator enthusiasm; (9) monitor the slow performers and sites with numerous personnel changes; (10) choose an endpoint that is easy to ascertain; (11) keep the trial simple for participants; and (12) plan early for closeout and for activities between the end of the trial and publication of results.</p></div>","PeriodicalId":72706,"journal":{"name":"Controlled clinical trials","volume":"24 6","pages":"Pages S316-S326"},"PeriodicalIF":0.0000,"publicationDate":"2003-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00099-0","citationCount":"2","resultStr":"{\"title\":\"Lessons learned from the DIG trial\",\"authors\":\"Debra Egan M.Sc., M.P.H. ,&nbsp;Nancy Geller Ph.D. ,&nbsp;Salim Yusuf M.B.B.S., F.R.C.P. ,&nbsp;Rekha Garg M.D., M.S. ,&nbsp;Joseph F. Collins Sc.D. ,&nbsp;James Mathew M.D. ,&nbsp;Edward Philbin M.D. ,&nbsp;on behalf of the DIG Investigators\",\"doi\":\"10.1016/S0197-2456(03)00099-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The Digitalis Investigation Group (DIG) trial was the first large simple trial conducted by the National Heart, Lung, and Blood Institute in conjunction with the Department of Veterans Affairs. A large simple trial is a major undertaking. Simplification at the sites requires careful planning and discipline. Lessons learned from the DIG trial were: (1) keep a large simple trial very simple and keep all study procedures very simple; (2) ancillary studies are important and can complement a large simple trial but require careful advanced planning; (3) anticipate special needs when shipping study drugs internationally; (4) regional coordinating centers can be very useful; (5) recruit as many capable sites as possible; (6) provide research-inexperienced sites/investigators with extra help to obtain federalwide assurance statements from the Office for Human Research Protections and institutional review board approvals; (7) adequately reimburse sites for the work completed; (8) maintain investigator enthusiasm; (9) monitor the slow performers and sites with numerous personnel changes; (10) choose an endpoint that is easy to ascertain; (11) keep the trial simple for participants; and (12) plan early for closeout and for activities between the end of the trial and publication of results.</p></div>\",\"PeriodicalId\":72706,\"journal\":{\"name\":\"Controlled clinical trials\",\"volume\":\"24 6\",\"pages\":\"Pages S316-S326\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2003-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S0197-2456(03)00099-0\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Controlled clinical trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0197245603000990\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Controlled clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0197245603000990","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

洋地黄研究组(DIG)试验是由国家心脏、肺和血液研究所与退伍军人事务部联合进行的第一个大型简单试验。一项大型的简单试验是一项重大任务。场地的简化需要仔细的规划和纪律。从DIG试验中得到的教训是:(1)使大型简单试验非常简单,并使所有研究程序非常简单;(2)辅助研究很重要,可以作为大型简单试验的补充,但需要事先仔细规划;(三)在国际运输研究药品时预见到特殊需求;(4)区域协调中心非常有用;(5)尽可能多地招募有能力的人员;(6)为缺乏研究经验的站点/调查员提供额外帮助,以获得人类研究保护办公室的联邦保证声明和机构审查委员会的批准;(七)对已完成的工作给予充分的补偿;(8)保持调查热情;(9)监督业绩不佳和人员变动较多的场所;(十)选择易于确定的终点;(11)使试验对参与者保持简单;(12)尽早计划结束和试验结束至结果公布之间的活动。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Lessons learned from the DIG trial

The Digitalis Investigation Group (DIG) trial was the first large simple trial conducted by the National Heart, Lung, and Blood Institute in conjunction with the Department of Veterans Affairs. A large simple trial is a major undertaking. Simplification at the sites requires careful planning and discipline. Lessons learned from the DIG trial were: (1) keep a large simple trial very simple and keep all study procedures very simple; (2) ancillary studies are important and can complement a large simple trial but require careful advanced planning; (3) anticipate special needs when shipping study drugs internationally; (4) regional coordinating centers can be very useful; (5) recruit as many capable sites as possible; (6) provide research-inexperienced sites/investigators with extra help to obtain federalwide assurance statements from the Office for Human Research Protections and institutional review board approvals; (7) adequately reimburse sites for the work completed; (8) maintain investigator enthusiasm; (9) monitor the slow performers and sites with numerous personnel changes; (10) choose an endpoint that is easy to ascertain; (11) keep the trial simple for participants; and (12) plan early for closeout and for activities between the end of the trial and publication of results.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Editorial Board On the generation and ownership of alpha in medical studies Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels Geographic variability in patient characteristics, treatment and outcome in an international trial of magnesium in acute myocardial infarction Analyzing bronchodilation with emphasis on disease type, age and sex
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1